Search for: "Ortho McNeil Pharmaceutical"
Results 1 - 20 of 103
Sorted by Relevance | Sort by Date
9 Apr, 2008 8:49 pm
By Donald Zuhn -- Last week, the Federal Circuit issued an opinion in Ortho-McNeil Pharmaceutical, Inc. v. Mylan Laboratories, Inc. In Mylan Laboratories, the Federal Circuit determined that the District Court for the District of New Jersey
properly construed claim 1 of U.S. Patent No. 4,513,006, owned by Plaintiff-Appellee Ortho-McNeil...
26 Aug 9:59 pm
... -part an order by the District Court for the District of New Jersey granting summary judgment of invalidity of U.S. Reissued Patent No. 39,221 based on anticipation and obviousness.
Plaintiff-Appellant Ortho-McNeil Pharmaceutical, Inc. owns
the '221 patent, which relates to a tramadol and acetaminophen composition for use in prescription pain relief. Ortho first claimed this
composition in U.S. Patent No. 5,336,691, and after receiving FDA approval, began ...
6 Apr, 2008 9:15 pm
By Donald Zuhn -- Last week, the Federal Circuit determined that the District Court for the District of New Jersey properly construed claim 1 of U.S. Patent No. 4,513,006 to encompass
Plaintiff-Appellee Ortho-McNeil Pharmaceutical, Inc.'s
epilepsy drug topiramate, and affirmed the District Court's decision to (1) permanently enjoin Defendants-Appellees Mylan...
22 Jan, 2007 6:39 pm
Intrinsic Evidence Pointing to a Criticality of a Claimed Ratio Used to Construe the Term "About." (Fed. Cir. 2007, 06-1102) Caraco filed an ANDA with the intent to make and sell a
pharmaceutical composition containing tramadol and acetaminophen with an average weight ratio of tramadol to acetaminophen of 1:8.67, and no
less than a ratio of 1:7.5. In response, Ortho [...]
10 Jun 9:02 pm
... Court for the Northern District of West Virginia awarding $1,011,712 in costs to Plaintiff-Appellee Daiichi Pharmaceutical Co., and
remanded to the District Court for an apportionment determination of the awarded costs. Daiichi owns U.S. Patent No. 5,053, ... ®. Seeking approval to market a generic version of
levofloxacin, Defendants-Appellants Mylan Laboratories Inc. and Mylan Pharmaceuticals Inc. filed an Abbreviated New Drug Application (ANDA) with the FDA. In response to Mylan's
ANDA filing,...
11 Apr, 2008 8:48 am
... -McNeil kept it's exclusivity on topiramate after a district court blocked Mylan Labs from infringing Ortho-McNeil's U.S. Patent No. 4,513,006 covering Topomax® (topiramate), ... affirmed the district court rulings on
claim construction, inequitable conduct, obviousness, and enablement. Ortho-Mcneil Pharmaceutical v. Mylan Laboratories (07-1223). Mylan filed an ANDA with the FDA with a paragraph IV certification asserting that Ortho-McNeil's '006 patent is invalid or not infringed. Ortho-McNeil sent ...
21 Jan, 2007 8:53 pm
... combining tramadol and acetaminophen, generated sales of approximately $350 million last year for Ortho-McNeil. Caraco is majority-owned by Sun Pharmaceutical, the fifth largest generic drug maker in India, while
Ortho-McNeil is a wholly ... claim 6 of the '691 patent, which recites (when read in conjunction with
the two claims on which it depends): "A pharmaceutical composition comprising a tramadol material and acetaminophen, wherein the ratio of the
tramadol material to acetaminophen is a weight ...
7 Apr, 2008 2:09 pm
... against the makers of medical devices like pacemakers are pre-empted.... What had not gotten as much attention was Ortho-McNeil's written response to this April 6 NYT article that the drug company published on their website. One ... "Issue: Should We Be Prohibited From Filing
Product Liability Lawsuits Against Medical Device Manufacturers And Pharmaceutical Companies?": According to some critics, the prohibition of
drug injury lawsuits by operation of the federal preemption doctrine may have some ...
14 Dec, 2006 4:11 pm
... Ortho-Evra birth control patch is filing a wrongful death suit against pharmaceutical house
Ortho-McNeil for wrongful death. Celena Devault, 26, died from blood clots and a pulmonary embolism
in June (03) after having started to use the Ortho-Evra patch two months earlier (APR03). The suit holds Ortho- ... responsible for Devault's death, and accuses Ortho-McNeil of
deliberately withholding information about the dangerous side effects of the drug, which includes blood clots, stroke, pulmonary ...
29 Apr, 2008 7:49 pm
... . RE39,221 are invalid as obvious. The '221 patent claims combinations of acetaminophen and tramadol, marketed by Ortho-McNeil (OMI) as Ultracet. Barr and Caraco are challenging the patent. OMI had previously asserted U.S. ... the ratio range claimed in the '221 patent.
Nevertheless, the '589 patent uses "consisting of" language in its description of the pharmaceutical formulations. In an anticipation context,
this "consisting of" language would prevent the '589 patent's four-agent formulations from ...
23 Jul, 2007 9:13 pm
By Sherri Oslick -- Ortho-McNeil, Inc. announced late last week that it has settled its lawsuit
against Par Pharmaceutical Companies, Inc. and its subsidiaries, Par Pharmaceutical, Inc. and Kali
Laboratories, Inc., over the patent covering Ortho's Ultracet® (tramadol hydrochloride and acetaminophen, used to treat acute pain). As part of
the...
27 Jul 3:32 am
... 24, 2009, Teva issued the following statement at Business Wire: Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) announced today that it
has entered into a definitive agreement with Ortho-McNeil-Janssen to settle the patent infringement
lawsuit in the U.S. District Court for the District of New Jersey related to Teva's generic version of the oral contraceptive, Ortho
Tri-Cyclen® Lo. Under the terms of the settlement, Teva will obtain a release for past sales of its generic product, in ...
26 Aug 9:20 am
ORTHO-MCNEIL PHARMACEUTICAL v. TEVA is a patent law appeal
from a D NJ order granting summary judgment of invalidity based on anticipation and obviousness, related to the drug Ultracet. In view of the ... 5, 2009) (affirming an obviousness
determination where the patentee was confronted with a limited number of options for modifying a prior art pharmaceutical composition). The
bottom line is that the patentee won, as to eliminating the summary judgment. Trial remains. We therefore vacate the district ...
5 Nov, 2006 2:15 pm
... from various serious side effects caused by blood clots related to the women's use of the Ortho Evra birth control patch. In September 2006
the FDA warned doctors and patients that ... California Ortho Evra lawsuits filed in November 2006 are the drug's manufacturer, Ortho-McNeil Pharmaceutical Co., a subsidiary of Johnson & Johnson
(J&J), and San Francisco-based distributor McKesson Corp. In September 2006 the Ortho Evra package insert, or label, was updated by J&J
to make doctors and ...
19 Mar, 2007 12:05 pm
... . The Ortho Evra birth control patch (known more familiarly as "the Patch") was introduced on the market in 2002 by Ortho McNeil Pharmaceutical Inc., a division of Johnson & Johnson, as
an alternative to the birth control pill. The Patch was marketed as being ... . Members of Burg Simpson served on discovery committee. $60,000,000: Global settlement involving defective
pharmaceutical product. Members of Burg Simpson served on discovery committee. $25,000,000: Confidential settlements for clients ...
21 Jan, 2008 1:23 pm
... . The BCDSP study, which looked at women aged 15 to 44, supported the i3 Ingenix findings. Ortho Evra is made by Ortho McNeil Pharmaceuticals, a Johnson and Johnson division. According to Bloomberg News, the company has
been sued by ... made public a letter from a former Johnson & Johnson executive who alleged that the company improperly downplayed the risks associated with the Ortho Evra patch. The author of the letter said that he had investigated an "unusually high number" of blood clots and ...
19 Jan, 2008 3:29 pm
... latest news about the Ortho Evra Contraceptive Transdermal (Skin) Patch manufactured by Ortho-McNeil Pharmaceuticals, a division of Johnson & Johnson (JNJ): The FDA today strengthened its
warning on the risk of serious blood clots in women using the ... veins as were women who used oral contraceptives. As background, in November 2005 the FDA announced a label change for
Ortho Evra to warn that the use of this contraceptive patch exposes women to higher levels of estrogen than a typical birth ...
18 Oct, 2006 6:23 pm
... to the nature, extent, and number, of patients who have sustained serious personal injury and even death as the result of use of Ortho
Evra.). The likely reasons for the rapid settlements are twofold and clear: (1) the manufacturer (Johnson & Johnson, a division of Ortho-McNeil Pharmaceutical Inc) wants to keep a lid on things by
requiring 'confidentiality'; and (2) the causal relationship between the injuries and the product are ...
25 Aug, 2006 6:55 pm
A law suit has been filed against Ortho-McNeil Pharmaceutical, Inc., a division of Johnson and Johnson Inc. (NYSE:JNJ), on behalf of a 34 year-old woman. The woman was diagnosed with a severe pulmonary
embolism after using the Ortho Evra birth control patch less than two years. The suit was filed in the United States District Court for the
District of New Jersey earlier this month.
18 Oct, 2006 5:06 pm
Users of the Ortho Evra birth control patch are cautioned to consult with their physicians about ongoing usage of this drug. The manufacturer
of this patch, Ortho-McNeil Pharmaceutical Inc, lists many
potential side effects to be aware of.
Search on: Blawgs.FM | BlawgSearch Google Co-op |
Blawg.com | Bloglines | Feedster | Google Blog Search |
Technorati | Google | MSN | Yahoo!